MaaT shoots for EU approval
But the timeline for a US green light is less clear, and the group has a cash crisis.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Microbiome make or break time for MaaT Pharma
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
